MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...
Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...
Even when patients with acute myeloid leukemia (AML) appear to be in remission, small numbers of cancer cells can remain in the body. These lingering cells—known as measurable residual disease ...
SEATTLE, July 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...
Adaptive Biotechnologies and NeoGenomics have announced a multi-year strategic collaboration to enhance minimal residual disease (MRD) monitoring for patients with specific blood cancers. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results